Lidocaine-Liqvo 1% 20ml Solution

Form

khsnari

Dosage mg

0.02

Pack

1

Product Trade Name: Lidocaine-Liquor Synonyms: Lignocaine, Lidocaine Hydrochloride, Xylocaine, Lidokart. Dosage Form: Solution for injection 2% and 1% Composition: Active substance: Lidocaine hydrochloride 20 mg/ml and 10 mg/ml Excipients: Sodium chloride. Description: The preparation is a colorless or slightly yellowish transparent liquid. Pharmacotherapeutic Group: Local anesthetic, Class I-B antiarrhythmic agent. Pharmacological Properties: Lidocaine is an acetanilide derivative with local anesthetic and antiarrhythmic action. It causes all types of local anesthesia: terminal, infiltration, and conduction. It is absorbed quite rapidly from mucous membranes and can cause systemic effects. Lidocaine is a Class I-B antiarrhythmic drug, effective for ventricular arrhythmias and extrasystoles. Lidocaine has a membrane-stabilizing effect. It blocks sodium channels in myocardial cells, which leads to suppression of the automaticity of ectopic foci in the myocardium. It does not affect myocardial conductivity. Lidocaine promotes the outflow of potassium ions from myocardial cells and accelerates the repolarization process of cell membranes, while reducing the action potential and effective refractory period. At medium therapeutic doses, lidocaine practically does not suppress myocardial contractility and does not cause a decrease in atrioventricular conduction. Pharmacokinetics: Absorption: When lidocaine solution is administered parenterally, its absorption depends on the injection site, the dose of the preparation, and the presence of adrenaline. The maximum concentration of the preparation in blood plasma is observed 5 minutes after administration. Distribution: The preparation is distributed in all tissues of the body, mainly in well-perfused organs such as the heart, kidneys, brain, liver, spleen, and subsequently in adipose and muscle tissues. Its protein binding is approximately 50%. It crosses the placental barrier. Metabolism: The preparation is metabolized in the liver, forming two pharmacologically active metabolites. A small portion undergoes enterohepatic circulation. Elimination: The preparation is eliminated in the urine in the form of metabolites. Its half-life is 1-3 hours. Lidocaine elimination is reduced in patients with impaired liver function, heart failure, and shock, as well as in children over 70 years of age. Indications: Ventricular extrasystole and tachycardia, especially in the acute period of myocardial infarction, prevention of ventricular fibrillation, glycoside intoxication, cardiac surgery. Terminal, infiltration, conduction anesthesia; also for local anesthesia in dentistry, ophthalmology, otorhinolaryngology, obstetrics and gynecology, surgery, dermatology, blockade of peripheral nerves and nerve ganglia. In obstetrics: before episiotomy and during suturing. Dosage and Administration: Cardiology practice: Administration of the preparation begins with an intravenous bolus dose of 1 mg/kg. To maintain its therapeutic concentration in the blood, lidocaine infusion is repeated at a dose of 0.5 mg/kg every 8-10 minutes, if necessary, up to a total dose of 3 mg/kg. After the first dose, maintenance infusion is started at 2-4 mg/min (30-50 mcg/kg/min); drip infusion can be continued for 24-36 hours. For infusion, 2% Lidocaine-Liquor solution is diluted to a concentration of 2-4 mg/ml in isotonic sodium chloride solution. In patients with heart failure, shock, impaired liver function, and those over 70 years of age, the initial or maintenance dose is reduced by 50%. In such cases, dynamic monitoring of lidocaine concentration in blood plasma is necessary during prolonged infusion. Endotracheal and intramuscular administration is used only when intravenous administration is impossible. Lidocaine is administered intramuscularly at a dose of 2-4 mg/kg (maximum single dose is 200 mg) at intervals of 4-6 hours. In case of myocardial infarction, 4 mg/kg (maximum - 200-300 mg) is administered before hospitalization. For use in surgery and obstetrics, dentistry, and ENT practice, the dosage regimen is determined individually based on indications, clinical situation, and the dosage form used. Lidocaine solution is compatible with epinephrine. If necessary, 1 drop of 0.1% epinephrine hydrochloride solution is added to 10 ml of the preparation (immediately before use), and no more than 5 drops in total solution. For local anesthesia, the maximum dose of the preparation is 200 mg, with epinephrine - 500 mg. Side Effects: Headache, dizziness, insomnia, restlessness. In patients with hypersensitivity, rapid intravenous administration of the preparation may cause convulsions, tremor, paresthesia, euphoria, disorientation, tinnitus, slowed speech. High doses of the preparation may cause bradycardia, slowed conduction, arterial hypotension. Contraindications: Marked bradycardia, hypovolemia, marked arterial hypotension, sinoatrial, atrioventricular or intraventricular blockades, cardiogenic shock, severe forms of chronic heart failure, hypersensitivity to the preparation and/or other amide-group local anesthetics, Adams-Stokes and Wolff-Parkinson-White syndromes. Overdose: Symptoms: Psychomotor agitation, tremor, convulsions, collapse, central nervous system depression. Treatment: Intravenous administration of short-acting barbiturates, use of benzodiazepine tranquilizers, if necessary, the patient is given oxygen, artificial ventilation of the lungs is performed, and other resuscitation methods are used. Vasopressors may be used to restore circulation. Special Instructions: Administer with caution to patients with chronic heart failure, arterial hypotension, severe impairment of liver or kidney function, impaired intraventricular conduction, sinus bradycardia, shock, hypovolemia. Barbiturates are prescribed 1 hour before high-dose lidocaine administration to induce anesthesia. In case of arterial hypotension developing against the background of lidocaine, sympathomimetic agents are administered intravenously; for bradycardia, 0.5-1 mg of atropine is administered intravenously. Lidocaine solution containing epinephrine cannot be used as an antiarrhythmic agent. Pregnancy and Lactation: During pregnancy and lactation, the preparation is prescribed for vital indications. Lidocaine is excreted in breast milk, so its use during lactation is not recommended. Interactions with Other Drugs: Simultaneous administration of lidocaine and beta-blockers may enhance the effect of lidocaine (including toxicity). Therefore, the dose of lidocaine should be reduced in such cases. It is irrational to administer lidocaine simultaneously with amiodarone, verapamil, quinidine, and diphenine due to the potentiation of cardiodepressive effects. Simultaneous administration of lidocaine with procainamide may cause central nervous system excitation and hallucinations. Intravenous administration of hexenal and thiopental sodium against the background of lidocaine action may cause respiratory center depression. Caution is required with the combination of lidocaine and phenytoin, as an undesirable cardiodepressive effect is expected. MAO inhibitors may enhance the local anesthetic effect of lidocaine. With the simultaneous use of lidocaine and polymyxin, the latter's interaction may suppress neuromuscular conduction with lidocaine used as an antiarrhythmic agent, so in this case, it is necessary to monitor the patient's respiratory function. Combination of lidocaine with hypnotics or sedatives may cause a depressant effect on the central nervous system. In patients receiving cimetidine, drowsiness, bradycardia, paresthesia, and others may occur with intravenous lidocaine administration. In this case, the dose of lidocaine should be reduced. Storage Conditions: Store in a dry, protected from light and children place, at a temperature of 8-25°C. Shelf Life: 2 years. The preparation is not allowed to be used after the expiry date indicated on the packaging. Prescription only. Dosage Form: Lidocaine-Liquor 2% in 20 ml glass vials. Lidocaine-Liquor 1% in 20 ml glass vials. Manufacturer: Liquor-Pharmaceutical Armenia